Quantum News
Sign InSign Up
Back to News
research

MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
MiNK Therapeutics reported Q4 2025 earnings, highlighting progress in its allogeneic invariant natural killer T (iNKT) cell platform, designed to restore immune function across diseases. CEO Jennifer Buell emphasized the platform’s off-the-shelf advantage over conventional cell therapies, eliminating patient-specific manufacturing delays and reducing costs. The company outlined clinical development milestones, including upcoming data releases and regulatory timelines, though specific trial results were not disclosed during the call. Financial officer Melissa Orilall provided year-end figures, but detailed revenue or loss metrics were overshadowed by forward-looking statements on partnerships and commercialization plans. Analysts from H.C. Wainwright and B. Riley Securities questioned timelines and partnership potential, signaling investor focus on execution risks and market differentiation.
AI Audio Summary
0:00 / 0:00
Click to play
generated-image (58).png
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts159.17K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call March 31, 2026 8:30 AM EDT Company Participants Jennifer Buell - President, CEO & DirectorMelissa Orilall - Principal Financial Officer Conference Call Participants Stefanie Perna-Nacar - Agenus Inc.Emily Bodnar - H.C. Wainwright & Co, LLC, Research DivisionMayank Mamtani - B. Riley Securities, Inc., Research Division Presentation Operator Good morning, and welcome to MiNK Therapeutics Fourth Quarter and Year-End 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this event is being recorded. If anyone has any objections, you may disconnect at this time. I would now like to turn the conference over to Stefanie Perna-Nacar, Chief Communications Officer. Please go ahead. Stefanie Perna-NacarAgenus Inc. Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including notes related to our clinical development, regulatory and commercial plans, time lines for data releases and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer; Dr. Terese Hammond, Head of Development; and Melissa Orilall, Principal Financial and Accounting Officer. I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter. Dr. Buell. Jennifer BuellPresident, CEO & Director Thank you, Stefanie. Good morning, everyone. For those new to MiNK Therapeutics, we are advancing a clinically validated allogeneic invariant natural killer T cell platform, one that is fundamentally differentiated in its ability to restore and coordinate immune function across diseases or even an immune failure. And unlike conventional cell therapies, our MiNK iNKT cells are off the shelf. They are

Read Original

Tags

partnership

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.